BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goff DC. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity. Curr Neuropharmacol 2017;15:21-34. [PMID: 26915421 DOI: 10.2174/1570159x14666160225154812] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Kuzminova MV, Solokhina TА, Nochevkina AI. Motivation Disorders in Patients with Schizophrenia. Psychiatry 2022;20:65-73. [DOI: 10.30629/2618-6667-2022-20-3-85-97] [Reference Citation Analysis]
2 Martínez AL, Brea J, Rico S, de Los Frailes MT, Loza MI. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments. Int J Mol Sci 2021;22:9905. [PMID: 34576069 DOI: 10.3390/ijms22189905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
3 Wu Q, Huang J, Wu R. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia. Front Neurosci 2021;15:641047. [PMID: 33912003 DOI: 10.3389/fnins.2021.641047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Fone KCF, Watson DJG, Billiras RI, Sicard DI, Dekeyne A, Rivet JM, Gobert A, Millan MJ. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management. Mol Neurobiol 2020;57:2144-66. [PMID: 31960362 DOI: 10.1007/s12035-020-01875-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
5 Levine J. Clinical convergence of autism, schizophrenia, and Alzheimer’s disease: The case of social cognition. Neuroprotection in Autism, Schizophrenia and Alzheimer's Disease 2020. [DOI: 10.1016/b978-0-12-814037-6.00002-1] [Reference Citation Analysis]
6 Zádor F, Nagy-Grócz G, Kekesi G, Dvorácskó S, Szűcs E, Tömböly C, Horvath G, Benyhe S, Vécsei L. Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules 2019;24:E3709. [PMID: 31619006 DOI: 10.3390/molecules24203709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
7 Bodkin JA, Coleman MJ, Godfrey LJ, Carvalho CMB, Morgan CJ, Suckow RF, Anderson T, Öngür D, Kaufman MJ, Lewandowski KE, Siegel AJ, Waldstreicher E, Grochowski CM, Javitt DC, Rujescu D, Hebbring S, Weinshilboum R, Rodriguez SB, Kirchhoff C, Visscher T, Vuckovic A, Fialkowski A, McCarthy S, Malhotra D, Sebat J, Goff DC, Hudson JI, Lupski JR, Coyle JT, Rudolph U, Levy DL. Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biol Psychiatry 2019;86:523-35. [PMID: 31279534 DOI: 10.1016/j.biopsych.2019.04.031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
8 Hansen IH, Agerskov C, Arvastson L, Bastlund JF, Sørensen HBD, Herrik KF. Pharmaco-electroencephalographic responses in the rat differ between active and inactive locomotor states. Eur J Neurosci 2019;50:1948-71. [PMID: 30762918 DOI: 10.1111/ejn.14373] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
9 Yung AR, Nelson B, McGorry PD, Wood SJ, Lin A. Persistent negative symptoms in individuals at Ultra High Risk for psychosis. Schizophr Res 2019;206:355-61. [PMID: 30482643 DOI: 10.1016/j.schres.2018.10.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
10 Kargbo RB. Modulating GluN2B for the Treatment of Neurological and Psychiatric Disorders. ACS Med Chem Lett 2017;8:905-7. [PMID: 28947933 DOI: 10.1021/acsmedchemlett.7b00309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017;16:14-24. [PMID: 28127915 DOI: 10.1002/wps.20385] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017;16:14-24. [PMID: 28127915 DOI: 10.1002/wps.20385] [Cited by in Crossref: 227] [Cited by in F6Publishing: 233] [Article Influence: 45.4] [Reference Citation Analysis]
13 Yao L, Zhou Q. Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators. Neural Plast 2017;2017:2875904. [PMID: 28163934 DOI: 10.1155/2017/2875904] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
14 Mitra S, Mahintamani T, Kavoor AR, Nizamie SH. Negative symptoms in schizophrenia. Ind Psychiatry J 2016;25:135-44. [PMID: 28659691 DOI: 10.4103/ipj.ipj_30_15] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]